Aimmune Therapeutics Inc (NASDAQ:AIMT) insider Mary M. Rozenman sold 1,807 shares of the company’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $33.10, for a total value of $59,811.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Aimmune Therapeutics Inc (NASDAQ:AIMT) traded up $0.28 during midday trading on Wednesday, hitting $33.28. The company had a trading volume of 709,999 shares, compared to its average volume of 1,025,934. Aimmune Therapeutics Inc has a 52-week low of $15.97 and a 52-week high of $42.00. The firm has a market cap of $1,720.00 and a P/E ratio of -16.08.
A number of large investors have recently bought and sold shares of AIMT. Carillon Tower Advisers Inc. purchased a new stake in Aimmune Therapeutics in the fourth quarter valued at $58,838,000. Alliancebernstein L.P. boosted its holdings in Aimmune Therapeutics by 109.5% in the fourth quarter. Alliancebernstein L.P. now owns 1,400,281 shares of the biotechnology company’s stock valued at $52,959,000 after purchasing an additional 731,927 shares during the last quarter. Citadel Advisors LLC boosted its holdings in Aimmune Therapeutics by 3,092.5% in the third quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock valued at $13,873,000 after purchasing an additional 542,111 shares during the last quarter. Franklin Resources Inc. purchased a new stake in Aimmune Therapeutics in the fourth quarter valued at $18,702,000. Finally, Vanguard Group Inc. boosted its holdings in Aimmune Therapeutics by 12.6% in the second quarter. Vanguard Group Inc. now owns 2,476,836 shares of the biotechnology company’s stock valued at $50,923,000 after purchasing an additional 276,978 shares during the last quarter. 62.04% of the stock is currently owned by institutional investors.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research downgraded Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. BidaskClub raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 8th. Wedbush reissued a “buy” rating on shares of Aimmune Therapeutics in a research report on Friday, February 23rd. Credit Suisse Group set a $45.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a research report on Tuesday, February 27th. Finally, Roth Capital upped their target price on Aimmune Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $57.22.
COPYRIGHT VIOLATION WARNING: “Aimmune Therapeutics Inc (NASDAQ:AIMT) Insider Mary M. Rozenman Sells 1,807 Shares” was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/03/14/mary-m-rozenman-sells-1807-shares-of-aimmune-therapeutics-inc-aimt-stock.html.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.